Arcellx is a clinical-stage biotech company based in Maryland that is focused on engineering immunotherapies for patients with cancer and other incurable diseases. Their lead product candidate, CART-ddBCMA, is being studied for the treatment of relapsed or refractory multiple myeloma. The company is also developing a dosable and controllable CAR-T therapy called ARC-SparX for the treatment of acute myeloid leukemia. Arcellx has received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations from the FDA. Their mission is to advance humanity by developing safer, more effective, and more accessible cell therapies.